Drugs / BMB-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05397041 | Jun 2022 → May 2023 | — | Bright Minds Biosciences Pty Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07266324 | Jan → Nov 2026 expected | Prader-Willi syndrome | Bright Minds Biosciences Pty Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06401538 | Dec 2024 → Sep 2025 overdue | Dravet syndrome, Lennox-Gastaut syndrome | Bright Minds Biosciences Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-01-06 | Bright Minds Biosciences Pty Ltd | Results Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) brightmindsbio.com ↗
today announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies. |
| 2025-05-13 | Bright Minds Biosciences Pty Ltd | Results Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 brightmindsbio.com ↗ |
| 2023-08-08 | Bright Minds Biosciences Pty Ltd | Results Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data fromits First-in-Human Phase 1 Study of Lead Compound, BMB-101 brightmindsbio.com ↗
BMB-101 demonstrated robust increase in central delta power and robust reduction in central alpha and beta power in active group, as previously reported for Anti-Epileptic Drugs (AEDs) in healthy individuals. |
| 2023-07-20 | Bright Minds Biosciences Pty Ltd | Results Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 brightmindsbio.com ↗
BMB-101 demonstrated an excellent safety and tolerability profile. |
| 2021-08-18 | Bright Minds Biosciences Pty Ltd | Results Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity brightmindsbio.com ↗
today announced that studies conducted with its BMB proprietary 5-HT2C agonist, BMB-101, showed efficacy in rodent models of Dravet Syndrome (“Dravet Syndrome”)/Epilepsy. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06401538 ↗ |
| Route | Oral | “Participants receiving BMB-101 orally” NCT05397041 ↗ |